Cyclobenzaprine

Mechanism :

Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. It is ineffective in muscle spasm due to central nervous system disease. Evidence suggests that the net effect of cyclobenzaprine is a reduction of tonic somatic motor activity, influencing both gamma (?) and alpha (a) motor systems.

Indication :

Relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Contraindications :

Hypersensitivity to any component of this product. Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis, seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs. Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure and hyperthyroidism.

Dosing :

<15 years:

Safety and efficacy not established.

>15 years:

5 mg three times a day.

Adverse Effect :

Drowsiness, dizziness, dry mouth, abdominal pain, acid regurgitation, constipation, diarrhea, nausea, irritability, mental acuity decreased, nervousness.

Interaction :

MAO inhibitors: May have life-threatening interactions with MAO inhibitors.
Alcohol, Barbiturates, and other CNS depressants: May enhance the effects of alcohol, barbiturates, and other CNS depressants.

Hepatic Dose :

Mild hepatic impairment: Start with 5 mg PO and increase the dose gradually with less frequent dosing than the three times daily schedule.
Moderate to severe hepatic impairment: Use is contraindicated.